Patients with PD-L1-negative non-small cell lung cancer experienced longer progression-free survival with sac-TMT plus ...

Surgery should remain the primary treatment for people with early-stage non-small cell lung cancer (NSCLC) who are suitable ...

With November marking Lung Cancer Awareness Month, medical experts are urging eligible residents to get screened before ...

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab ...

Lung cancer care is advancing through earlier detection and personalized, multidisciplinary treatment: long-term data show adjuvant osimertinib improves survival for some patients with EGFR-mutated ...

Adding Imdelltra (tarlatamab) to Imfinzi (durvalumab) maintenance therapy helped people with extensive-stage small cell lung ...

(Corrects first bullet point showing median survival for trial patients as 21.1 months vs. 12.7 months, not 21.7 months vs 12 ...

People with small-cell lung cancer could live significantly longer on a novel immunotherapy, even when their cancer has spread, Phase 3 trial results show.

The survival rate for people with lung cancer is improving, according to the new State of Lung Cancer report. The American Lung Association report says there have been important advances in early ...

Final randomized PAPILLON results found a six-month median overall-survival advantage with amivantamab plus chemotherapy in ...